JP2025502266A5 - - Google Patents
Info
- Publication number
- JP2025502266A5 JP2025502266A5 JP2024541996A JP2024541996A JP2025502266A5 JP 2025502266 A5 JP2025502266 A5 JP 2025502266A5 JP 2024541996 A JP2024541996 A JP 2024541996A JP 2024541996 A JP2024541996 A JP 2024541996A JP 2025502266 A5 JP2025502266 A5 JP 2025502266A5
- Authority
- JP
- Japan
- Prior art keywords
- upadacitinib
- receiving
- cyp3a4 inhibitor
- patient
- period
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263299324P | 2022-01-13 | 2022-01-13 | |
| US63/299,324 | 2022-01-13 | ||
| US202263320149P | 2022-03-15 | 2022-03-15 | |
| US63/320,149 | 2022-03-15 | ||
| PCT/US2023/060648 WO2023137440A2 (en) | 2022-01-13 | 2023-01-13 | Method of administering upadacitinib to avoid adverse drug interactions and effects |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025502266A JP2025502266A (ja) | 2025-01-24 |
| JP2025502266A5 true JP2025502266A5 (cg-RX-API-DMAC7.html) | 2026-01-22 |
Family
ID=87279802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024541996A Pending JP2025502266A (ja) | 2022-01-13 | 2023-01-13 | 有害な薬物相互作用及び影響を回避するためにウパダシチニブを投与する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230233555A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4463161A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025502266A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240148324A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023206381A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3246767A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024008557A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023137440A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12570664B2 (en) | 2015-10-16 | 2026-03-10 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US12365689B2 (en) | 2015-10-16 | 2025-07-22 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| SG10201913990RA (en) | 2015-10-16 | 2020-03-30 | Abbvie Inc | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11564922B2 (en) * | 2017-03-09 | 2023-01-31 | Abbvie Inc. | Methods of treating crohn's disease and ulcerative colitis |
| AU2018230500B2 (en) * | 2017-03-09 | 2024-03-07 | Abbvie Inc. | Methods of treating Crohn's disease and ulcerative colitis |
| US10857144B2 (en) * | 2017-05-16 | 2020-12-08 | Bow River LLC | Methods of treatment |
-
2023
- 2023-01-13 KR KR1020247024707A patent/KR20240148324A/ko active Pending
- 2023-01-13 CA CA3246767A patent/CA3246767A1/en active Pending
- 2023-01-13 AU AU2023206381A patent/AU2023206381A1/en active Pending
- 2023-01-13 MX MX2024008557A patent/MX2024008557A/es unknown
- 2023-01-13 JP JP2024541996A patent/JP2025502266A/ja active Pending
- 2023-01-13 EP EP23740880.2A patent/EP4463161A4/en active Pending
- 2023-01-13 WO PCT/US2023/060648 patent/WO2023137440A2/en not_active Ceased
- 2023-03-28 US US18/127,211 patent/US20230233555A1/en not_active Abandoned